Revelation Biosciences

REVB

Market cap $3.57M

SAN DIEGO, CA / ACCESS Newswire / May 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today reported its financial results for the three months ended March 31, 2026. Corporate Highlights Announced agreement with FDA on a single adaptive Phase 2/3 study for approval of Gemini for treatment of acute kidney injury Received net proceeds of $6.7 million from warrant inducement in January 2026 Participated in a fireside chat at the 38th Annual ROTH Conference, during which management discussed the Company's developments and strategic priorities Presented additional positive data analysis from the PRIME Study at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) in San Diego (March 29 - April 1, 2026) Initiated discussions with potential clinical research organizations for the single adaptive Phase 2/3 study "The incredible momentum achieved in 2025 is continuing in 2026," said James Rolke, Chief Executive Officer of Revelation.

SAN DIEGO, CA / ACCESS Newswire / April 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced formation of an Acute Kidney Injury (AKI) Advisory Board for the upcoming Phase 2/3 AKI clinical trial. This distinguished panel brings together internationally recognized Nephrologists and Critical Care Physicians who will guide the company's clinical strategy, monitor progress, and ensure the initiative achieves the goal of improving patient care by advancing Gemini for the treatment of AKI.

- A majority of CKD patients present with cellular inflammation and immunoparalysis predose - -Gemini durably normalizes cellular inflammation and restores immunocompetence - SAN DIEGO, CA / ACCESS Newswire / March 30, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on innovative solutions for acute and chronic disease, presented additional positive data analysis from the PRIME Study at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) in San Diego (March 29 - April 1, 2026). Presented datademonstrated the capability of Gemini to normalize the hyperinflammatory state and restore immunocompetence up to 7 days after a single dose, in stage 3 and 4 chronic kidney disease (CKD) patients peripheral blood mononuclear cells.

SAN DIEGO, CA / ACCESS Newswire / March 24, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today announced a reminder of its participation in a fireside chat on Tuesday, March 24, 2026, at 2:00 p.m. PT, as part of the 38th Annual Roth Conference, in Dana Point, CA.

SAN DIEGO, CA / ACCESS Newswire / March 19, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, announced today that James Rolke, Revelation's Chief Executive Officer, and Chester S. Zygmont, III, Revelation's Chief Financial Officer, will be attending the 38th Annual Roth Conference, in Dana Point, CA, on Monday and Tuesday March 23rd and 24th.

SAN DIEGO, CA / ACCESS Newswire / February 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today reported its financial results for the three and twelve months ended December 31, 2025. Corporate Highlights Announced Positive Results from PRIME Clinical Study in late-stage chronic kidney disease patients Announced agreement with FDA on a single adaptive Phase 2/3 study for approval of Gemini for treatment of acute kidney injury Received net proceeds of $6.7 million from warrant inducement in January 2026 Clinical data on the potential therapeutic benefit of Gemini for the treatment of acute kidney injury (AKI) and chronic kidney disease (CKD) will be presented at the International Conference on Advances in Critical Care Nephrology in San Diego (March 29 - April 1, 2026) "2025 was a positive year for Revelation with significant advancement of the Gemini program," said James Rolke, Chief Executive Officer of Revelation.

SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), announced today that, on January 28, 2026, the Company will implement a 1-for-4 reverse split of its common stock. The reverse stock split will be effective as of the morning of January 28, 2026, and the Company's common stock will trade on a post-split basis at the beginning of trading on the same date under the existing trading symbol "REVB.

SAN DIEGO, CA / ACCESS Newswire / January 23, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, announced today the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 13,065,000 shares of common stock, issued by the Company on September 11, 2025 (the "Existing Warrants"), at reduced exercise price of $0.86 per share. The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to an effective registration statement on Form S-3 (File No.

- Single Phase 2/3 Adaptive Study Design - - Clinically Relevant, Objective Composite Endpoint - SAN DIEGO, CA / ACCESS Newswire / January 21, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation, announced that the Company has reached agreement with the FDA on an approval pathway for Gemini as a treatment for Acute Kidney Injury (AKI). The two key agreements were 1) a clinically relevant and objective composite endpoint comprising death and/or need for dialysis, and 2) positive data from a single well-controlled Phase 2/3 adaptive design clinical study, comprising approximately 300 patients, would be sufficient for submission of a new drug application (NDA).

- Presentation to Include Additional Positive Data from the Recently Completed PRIME Clinical Study - SAN DIEGO, CA / ACCESS Newswire / January 14, 2026 / Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation, announced today that new clinical data on the potential therapeutic benefit of Gemini for the treatment of acute kidney injury (AKI) and chronic kidney disease (CKD) will be presented at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) taking place in San Diego (March 29 - April 1, 2026). Presented data demonstrates normalization of the hyperinflammatory state in stage 3 and 4 CKD patients and restoration of immunocompetence.